Current Heart Failure Reports

, Volume 14, Issue 1, pp 40–47 | Cite as

Remote Monitoring to Reduce Heart Failure Readmissions

  • Sitaramesh EmaniEmail author
Pathophysiology of Myocardial Failure (I Anand and M Patarroyo-Aponte, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Pathophysiology of Myocardial Failure


Purpose of Review

Rehospitalization for heart failure remains a challenge in the treatment of affected patients. The ability to remotely monitor patients for worsening heart failure may provide an avenue through which therapeutic interventions can be made to prevent a rehospitalization. Available data on remote monitoring to reduce heart failure rehospitalizations are reviewed within.

Recent Findings

Strategies to reduce readmissions include clinical telemonitoring, bioimpedance changes, biomarkers, and remote hemodynamic monitoring. Telemonitoring is readily available, but has low sensitivity and adherence. No data exist to demonstrate the efficacy of this strategy in reducing admissions. Bioimpedance offers improved sensitivity compared to telemonitoring, but has not demonstrated an ability to reduce hospitalizations and is currently limited to those patients who have separate indications for an implantable device. Biomarker levels have shown variable results in the ability to reduce hospitalizations and remain without definitive proof supporting their utilization. Remote hemodynamic monitoring has shown the strongest ability to reduce heart failure readmissions and is currently approved for this purpose. However, remote hemodynamic monitoring requires an invasive procedure and may not be cost-effective.


All currently available strategies to reduce hospitalizations with remote monitoring have drawbacks and challenges. Remote hemodynamic monitoring is currently the most efficacious based on data, but is not without its own imperfections.


Readmissions Remote monitoring Bioimpedance Biomarkers Hemodynamic monitoring 


Compliance with Ethical Standards

Conflict of Interest

Sitaramesh Emani has received grant funding from St. Jude Medical, Inc. as well as travel reimbursement from Boston Scientific. He has also received grant support from Gilead Sciences and is on the advisory board of CareDX outside of the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606–19. doi: 10.1161/HHF.0b013e318291329a.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360(14):1418–28.CrossRefPubMedGoogle Scholar
  3. 3.
    Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154(2):260–6. doi: 10.1016/j.ahj.2007.01.041.CrossRefPubMedGoogle Scholar
  4. 4.
    Jovicic A, Holroyd-Leduc JM, Straus SE. Effects of self-management intervention on health outcomes of patients with heart failure: a systematic review of randomized controlled trials. BMC Cardiovasc Disord. 2006;6:43. doi: 10.1186/1471-2261-6-43.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Moser DK, Doering LV, Chung ML. Vulnerabilities of patients recovering from an exacerbation of chronic heart failure. Am Heart J. 2005;150(5):984. doi: 10.1016/j.ahj.2005.07.028.CrossRefPubMedGoogle Scholar
  6. 6.
    van der Wal MH, Jaarsma T, Moser DK, Veeger NJ, van Gilst WH, van Veldhuisen DJ. Compliance in heart failure patients: the importance of knowledge and beliefs. Eur Heart J. 2006;27(4):434–40. doi: 10.1093/eurheartj/ehi603.PubMedGoogle Scholar
  7. 7.
    Chaudhry SI, Mattera JA, Curtis JP, Spertus JA, Herrin J, Lin Z, et al. Telemonitoring in patients with heart failure. N Engl J Med. 2010;363(24):2301–9. doi: 10.1056/NEJMoa1010029.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Koehler F, Winkler S, Schieber M, Sechtem U, Stangl K, Bohm M, et al. Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation. 2011;123(17):1873–80. doi: 10.1161/CIRCULATIONAHA.111.018473.CrossRefPubMedGoogle Scholar
  9. 9.•
    Ong MK, Romano PS, Edgington S, Aronow HU, Auerbach AD, Black JT, et al. Effectiveness of remote patient monitoring after discharge of hospitalized patients with heart failure: The Better Effectiveness After Transition–Heart Failure (BEAT-HF) Randomized Clinical Trial. JAMA internal medicine. 2016;176(3):310–8. Most recent trial evaluating telemonitoring effects on reshospitalization.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Lewin J, Ledwidge M, O’Loughlin C, McNally C, McDonald K. Clinical deterioration in established heart failure: what is the value of BNP and weight gain in aiding diagnosis? Eur J Heart Fail. 2005;7(6):953–7. doi: 10.1016/j.ejheart.2005.06.003.CrossRefPubMedGoogle Scholar
  11. 11.
    Abraham WT, Compton S, Haas G, Foreman B, Canby RC, Fishel R, et al. Intrathoracic impedance vs daily weight monitoring for predicting worsening heart failure events: results of the Fluid Accumulation Status Trial (FAST). Congest Heart Fail. 2011;17(2):51–5. doi: 10.1111/j.1751-7133.2011.00220.x.CrossRefPubMedGoogle Scholar
  12. 12.
    • Adamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. Curr Heart Fail Rep. 2009;6(4):287–92. Review of pathophysiologic changes in heart failure prior to a heart failure hospitalization.CrossRefPubMedGoogle Scholar
  13. 13.
    Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW, Committee ASA, et al. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2007;153(6):1021–8. doi: 10.1016/j.ahj.2007.03.012.CrossRefPubMedGoogle Scholar
  14. 14.
    Khalil SF, Mohktar MS, Ibrahim F. The theory and fundamentals of bioimpedance analysis in clinical status monitoring and diagnosis of diseases. Sensors (Basel). 2014;14(6):10895–928. doi: 10.3390/s140610895.CrossRefGoogle Scholar
  15. 15.
    Hoffer O. Unilateral hyperplastic proliferations of the articular process. Arch Stomatol (Napoli). 1969;10(1):3–11.Google Scholar
  16. 16.
    Yu CM, Wang L, Chau E, Chan RH, Kong SL, Tang MO, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. 2005;112(6):841–8. doi: 10.1161/CIRCULATIONAHA.104.492207.CrossRefPubMedGoogle Scholar
  17. 17.
    Conraads VM, Tavazzi L, Santini M, Oliva F, Gerritse B, Yu CM, et al. Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations: the SENSE-HF trial. Eur Heart J. 2011;32(18):2266–73. doi: 10.1093/eurheartj/ehr050.CrossRefPubMedGoogle Scholar
  18. 18.
    Damman K. Ng Kam Chuen MJ, MacFadyen RJ, Lip GY, Gaze D, Collinson PO et al. Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J Am Coll Cardiol. 2011;57(22):2233–41. doi: 10.1016/j.jacc.2010.10.065.CrossRefPubMedGoogle Scholar
  19. 19.
    • Bohm M, Drexler H, Oswald H, Rybak K, Bosch R, Butter C, et al. Fluid status telemedicine alerts for heart failure: a randomized controlled trial. Eur Heart J. 2016. doi: 10.1093/eurheartj/ehw099. Recent trial attempting to use bioimpedance to reduce hospitalizations.PubMedCentralGoogle Scholar
  20. 20.
    Ahmad T, Fiuzat M, Pencina MJ, Geller NL, Zannad F, Cleland JG, et al. Charting a roadmap for heart failure biomarker studies. JACC Heart failure. 2014;2(5):477–88. doi: 10.1016/j.jchf.2014.02.005.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119(17):2408–16. doi: 10.1161/CIRCULATIONAHA.109.192278.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Januzzi Jr JL, Sakhuja R, O’Donoghue M, Baggish AL, Anwaruddin S, Chae CU, et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006;166(3):315–20. doi: 10.1001/archinte.166.3.315.CrossRefPubMedGoogle Scholar
  23. 23.
    Felker GM, Ahmad T, Anstrom KJ, Adams KF, Cooper LS, Ezekowitz JA, et al. Rationale and design of the GUIDE-IT study: guiding evidence based therapy using biomarker intensified treatment in heart failure. JACC Heart failure. 2014;2(5):457–65. doi: 10.1016/j.jchf.2014.05.007.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355(9210):1126–30.CrossRefPubMedGoogle Scholar
  25. 25.
    Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007;49(16):1733–9. doi: 10.1016/j.jacc.2006.10.081.CrossRefPubMedGoogle Scholar
  26. 26.
    Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti S, et al. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol. 2010;55(7):645–53. doi: 10.1016/j.jacc.2009.08.078.CrossRefPubMedGoogle Scholar
  27. 27.
    Gaggin HK, Mohammed AA, Bhardwaj A, Rehman SU, Gregory SA, Weiner RB, et al. Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study. J Card Fail. 2012;18(8):626–34. doi: 10.1016/j.cardfail.2012.05.005.CrossRefPubMedGoogle Scholar
  28. 28.
    Eurlings LW, van Pol PE, Kok WE, van Wijk S. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol. 2010;56(25):2090–100. doi: 10.1016/j.jacc.2010.07.030.CrossRefPubMedGoogle Scholar
  29. 29.
    Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol. 2009;55(1):53–60. doi: 10.1016/j.jacc.2009.02.095.CrossRefPubMedGoogle Scholar
  30. 30.
    Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301(4):383–92. doi: 10.1001/jama.2009.2.CrossRefPubMedGoogle Scholar
  31. 31.
    DCRI announces halt to GUIDE-IT trial. 2016. Accessed October 20, 2016.
  32. 32.
    Owens AT, Jessup M. The year in heart failure. J Am Coll Cardiol. 2011;57(15):1573–83. doi: 10.1016/j.jacc.2011.01.012.CrossRefPubMedGoogle Scholar
  33. 33.
    Stevenson LW, Tillisch JH, Hamilton M, Luu M, Chelimsky-Fallick C, Moriguchi J, et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol. 1990;66(19):1348–54.CrossRefPubMedGoogle Scholar
  34. 34.
    Morley D, Brozena SC. Assessing risk by hemodynamic profile in patients awaiting cardiac transplantation. Am J Cardiol. 1994;73(5):379–83.CrossRefPubMedGoogle Scholar
  35. 35.
    • Stevenson LW, Zile M, Bennett TD, Kueffer FJ, Jessup ML, Adamson P, et al. Chronic ambulatory intracardiac pressures and future heart failure events. Circ Heart Fail. 2010;3(5):580–7. doi: 10.1161/CIRCHEARTFAILURE.109.923300. Review of data supporting the use of remote hemodynamic parameters to monitor heart failure status.CrossRefPubMedGoogle Scholar
  36. 36.
    • Bourge RC, Abraham WT, Adamson PB, Aaron MF, Aranda Jr JM, Magalski A, et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol. 2008;51(11):1073–9. doi: 10.1016/j.jacc.2007.10.061. Early phase trial data correlating remote hemodynamic monitoring with heart failure outcomes.CrossRefPubMedGoogle Scholar
  37. 37.
    Adamson PB, Gold MR, Bennett T, Bourge RC, Stevenson LW, Trupp R, et al. Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial. Congest Heart Fail. 2011;17(5):248–54. doi: 10.1111/j.1751-7133.2011.00247.x.CrossRefPubMedGoogle Scholar
  38. 38.
    Ritzema J, Melton IC, Richards AM, Crozier IG, Frampton C, Doughty RN, et al. Direct left atrial pressure monitoring in ambulatory heart failure patients: initial experience with a new permanent implantable device. Circulation. 2007;116(25):2952–9. doi: 10.1161/CIRCULATIONAHA.107.702191.CrossRefPubMedGoogle Scholar
  39. 39.
    Ritzema J, Troughton R, Melton I, Crozier I, Doughty R, Krum H, et al. Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure. Circulation. 2010;121(9):1086–95. doi: 10.1161/CIRCULATIONAHA.108.800490.CrossRefPubMedGoogle Scholar
  40. 40.
    Abraham WT, editor. Hemodynamic Monitoring in Advanced Heart Failure: Results from the LAPTOP-HF Trial. HFSA 20th Annual Scientific Meeting; 2016; Orlando, FL.Google Scholar
  41. 41.
    Adamson PB, Abraham WT, Aaron M, Aranda Jr JM, Bourge RC, Smith A, et al. CHAMPION trial rationale and design: the long-term safety and clinical efficacy of a wireless pulmonary artery pressure monitoring system. J Card Fail. 2011;17(1):3–10. doi: 10.1016/j.cardfail.2010.08.002.CrossRefPubMedGoogle Scholar
  42. 42.
    •• Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377(9766):658–66. doi: 10.1016/S0140-6736(11)60101-3. Results of the pivotal CHAMPION Trial showing efficacy of remote hemodynamic monitoring to reduce heart failure hospitalizations.CrossRefPubMedGoogle Scholar
  43. 43.
  44. 44.
    CardioMEMS HF System Post Approval Study. Accessed November 2, 2016.
  45. 45.
    Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7(6):935–44. doi: 10.1161/CIRCHEARTFAILURE.113.001229.CrossRefPubMedGoogle Scholar
  46. 46.
    Dhruva SS, Krumholz HM. Championing Effectiveness Before Cost-Effectiveness. JACC Heart Fail. 2016;4(5):376–9. doi: 10.1016/j.jchf.2016.02.001.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.The Ohio State University Wexner Medical CenterColumbusUSA

Personalised recommendations